← Back to Search

Diagnostic Test

positive for fetal aneuploidy for Down Syndrome (FAST1 Trial)

N/A
Waitlist Available
Led By Thomas J Musci, MD
Research Sponsored by BioCeryx
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 21 months
Awards & highlights

FAST1 Trial Summary

The purpose of this study is to develop and evaluate a blood test and automated microfluidic test platform for the prenatal screening of fetal aneuploidy.

Eligible Conditions
  • Down Syndrome

FAST1 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~21 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 21 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Comparison of blood test to fetal karyotype

FAST1 Trial Design

2Treatment groups
Experimental Treatment
Group I: positive for fetal aneuploidyExperimental Treatment1 Intervention
Group II: negative for fetal aneuploidyExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
blood test
2016
Completed Phase 3
~2500

Find a Location

Who is running the clinical trial?

University College London HospitalsOTHER
194 Previous Clinical Trials
1,169,602 Total Patients Enrolled
Brugmann University HospitalOTHER
119 Previous Clinical Trials
52,823 Total Patients Enrolled
Hospital Universitario Virgen de la ArrixacaOTHER
57 Previous Clinical Trials
21,705 Total Patients Enrolled
~253 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top